Consolidated Net Loss: Net loss for the three months ended June 30, 2013 was $29.1 million, or $0.06 per share, compared to a net loss of $25.9 million, or $0.05 per share, in the corresponding period in 2012. Net loss for the six months ended June 30, 2013 was $55.1 million, or $0.11 per share, compared to a net loss of $55.8 million, or $0.12 per share, for the corresponding period in 2012. For the three and six months ended June 30, 2013, net loss included non-cash, stock-based compensation expense of $1.9 million and $4.0 million, respectively. For the three and six months ended June 30, 2012, net loss included non-cash, stock-based compensation expense of $1.6 million and $3.3 million, respectively.
Cash and Investments: As of June 30, 2013, Lexicon had $175.4 million in cash and investments, as compared to $197.2 million as of March 31, 2013 and $223.2 million as of December 31, 2012.
Lexicon Conference CallLexicon management will hold a conference call to discuss its clinical development progress and financial results for the second quarter of 2013 at 11:00 a.m. Eastern Time on July 30, 2013. The dial-in number for the conference call is 888-645-5785 (within the US/Canada) or 970-300-1531 (international). The conference ID for all callers is 22881223. Investors can access a live webcast of the call at www.lexpharma.com. An archived version of the webcast will be available on the website through August 30, 2013.
About LexiconLexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease. Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were
|SOURCE Lexicon Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved